|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Al-Toubah T, Strosberg J,
Hallanger-Johnson J and El-Haddad G: Targeted radionuclide therapy
in endocrine-related cancers: Advances in the last decade. Front
Endocrinol (Lausanne). 14(1187870)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Salih S, Alkatheeri A, Alomaim W and
Elliyanti A: Radiopharmaceutical treatments for cancer therapy,
radionuclides characteristics, applications, and challenges.
Molecules. 27(5231)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Park UJ, Lee JS, Choi KH, Nam SS and Yu
KH: Lu-177 preparation for radiotherapy application. Appl Radiat
Isot. 115:8–12. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zakaly HMH, Mostafa MYA, Deryabina D and
Zhukovsky M: Comparative studies on the potential use of
177Lu-based radiopharmaceuticals for the palliative
therapy of bone metastases. Int J Radiat Biol. 96:779–789.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dash A, Pillai MR and Knapp FF Jr:
Production of (177)Lu for targeted radionuclide therapy: Available
options. Nucl Med Mol Imaging. 49:85–107. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tan HY, Yeong CH, Wong YH, McKenzie M,
Kasbollah A, Shah MNM and Perkins AC: Neutron-activated theranostic
radionuclides for nuclear medicine. Nucl Med Biol. 90-91:55–68.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cao J, Chen Y, Hu M and Zhang W:
177Lu-PSMA-RLT of metastatic castration-resistant
prostate cancer: Limitations and improvements. Ann Nucl Med.
35:861–870. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Boegemann M, Schrader AJ and Rahbar K:
177Lu-PSMA therapy: Current evidence for use in the
treatment of patients with metastatic prostate cancer. Urologe A.
56:1440–1444. 2017.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
10
|
Ghosh A and Heston WD: Tumor target
prostate specific membrane antigen (PSMA) and its regulation in
prostate cancer. J Cell Biochem. 91:528–539. 2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fendler WP, Rahbar K, Herrmann K,
Kratochwil C and Eiber M: 177Lu-PSMA radioligand therapy for
prostate cancer. J Nucl Med. 58:1196–1200. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sadaghiani MS, Sheikhbahaei S, Werner RA,
Pienta KJ, Pomper MG, Gorin MA, Solnes LB and Rowe SP:
177 Lu-PSMA radioligand therapy effectiveness in
metastatic castration-resistant prostate cancer: An updated
systematic review and meta-analysis. Prostate. 82:826–835.
2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Weineisen M, Schottelius M, Simecek J,
Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I,
Eiber M, et al: 68Ga- and 177Lu-labeled PSMA I&T: Optimization
of a PSMA-targeted theranostic concept and first proof-of-concept
human studies. J Nucl Med. 56:1169–1176. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Barna S, Haug AR, Hartenbach M, Rasul S,
Grubmüller B, Kramer G and Blaickner M: Dose calculations and
dose-effect relationships in 177Lu-PSMA I&T radionuclide
therapy for metastatic castration-resistant prostate cancer. Clin
Nucl Med. 45:661–667. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hartrampf PE, Weinzierl FX, Serfling SE,
Pomper MG, Rowe SP, Higuchi T, Seitz AK, Kübler H, Buck AK and
Werner RA: Hematotoxicity and nephrotoxicity in prostate cancer
patients undergoing radioligand therapy with [177Lu]Lu-PSMA
I&T. Cancers (Basel). 14(647)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bu T, Zhang L, Yu F, Yao X, Wu W, Zhang P,
Shi L, Zang S, Meng Q, Ni Y, et al: 177Lu-PSMA-I&T radioligand
therapy for treating metastatic castration-resistant prostate
cancer: A single-centre study in East Asians. Front Oncol.
12(835956)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Emmett L, John N, Pathmanandavel S,
Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan
G, et al: Patient outcomes following a response biomarker-guided
approach to treatment using 177Lu-PSMA-I&T in men with
metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv
Med Oncol. 15(17588359231156392)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Karimzadeh A, Heck M, Tauber R, Knorr K,
Haller B, D'Alessandria C, Weber WA, Eiber M and Rauscher I:
177Lu-PSMA-I&T for treatment of metastatic
castration-resistant prostate cancer: Prognostic value of
scintigraphic and clinical biomarkers. J Nucl Med. 64:402–409.
2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Golan S, Frumer M, Zohar Y, Rosenbaum E,
Yakimov M, Kedar D, Margel D, Baniel J, Steinmetz AP, Groshar D, et
al: Neoadjuvant 177Lu-PSMA-I&T radionuclide
treatment in patients with high-risk prostate cancer before radical
prostatectomy: A single-arm phase 1 trial. Eur Urol Oncol.
6:151–159. 2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Stasiuk GJ and Long NJ: The ubiquitous
DOTA and its derivatives: The impact of
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on
biomedical imaging. Chem Commun (Camb). 49:2732–2746.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Keam SJ: Lutetium Lu 177 vipivotide
tetraxetan: First approval. Mol Diagn Ther. 26:467–475.
2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu X, Fang GC, Lu H, Shi ZD, Chen ZS and
Han CH: Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Drugs Today (Barc). 59:37–49. 2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim YJ and Kim YI: Therapeutic responses
and survival effects of 177Lu-PSMA-617 radioligand therapy in
metastatic castrate-resistant prostate cancer: A meta-analysis.
Clin Nucl Med. 43:728–734. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Violet J, Sandhu S, Iravani A, Ferdinandus
J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A,
et al: Long-term follow-up and outcomes of retreatment in an
expanded 50-patient single-center phase II prospective trial of
177Lu-PSMA-617 theranostics in metastatic
castration-resistant prostate cancer. J Nucl Med. 61:857–865.
2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hofman MS, Violet J, Hicks RJ and Sandhu
S: [177Lu]-PSMA-617 radionuclide therapy in patients
with metastatic castration-resistant prostate cancer-Author's
reply. Lancet Oncol. 19(e373)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sartor O, de Bono J, Chi KN, Fizazi K,
Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N,
El-Haddad G, et al: Lutetium-177-PSMA-617 for metastatic
castration-resistant prostate cancer. N Engl J Med. 385:1091–1103.
2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hartrampf PE, Weinzierl FX, Buck AK, Rowe
SP, Higuchi T, Seitz AK, Kübler H, Schirbel A, Essler M, Bundschuh
RA and Werner RA: Matched-pair analysis of
[177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617
in patients with metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 49:3269–3276. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Schuchardt C, Zhang J, Kulkarni HR, Chen
X, Müller D and Baum RP: Prostate-specific membrane antigen
radioligand therapy using 177Lu-PSMA I&T and
177Lu-PSMA-617 in patients with metastatic
castration-resistant prostate cancer: Comparison of safety,
biodistribution, and dosimetry. J Nucl Med. 63:1199–1207.
2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fizazi K, Herrmann K, Krause BJ, Rahbar K,
Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, et
al: Health-related quality of life and pain outcomes with
[177Lu]Lu-PSMA-617 plus standard of care versus standard
of care in patients with metastatic castration-resistant prostate
cancer (VISION): A multicentre, open-label, randomised, phase 3
trial. Lancet Oncol. 24:597–610. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Niaz MO, Sun M, Ramirez-Fort MK and Niaz
MJ: Review of lutetium-177-labeled anti-prostate-specific membrane
antigen monoclonal antibody j591 for the treatment of metastatic
castration-resistant prostate cancer. Cureus.
12(e7107)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liu H, Rajasekaran AK, Moy P, Xia Y, Kim
S, Navarro V, Rahmati R and Bander NH: Constitutive and
antibody-induced internalization of prostate-specific membrane
antigen. Cancer Res. 58:4055–4060. 1998.PubMed/NCBI
|
|
33
|
Batra JS, Niaz MJ, Whang YE, Sheikh A,
Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM,
Nanus DM, et al: Phase I trial of docetaxel plus
lutetium-177-labeled anti-prostate-specific membrane antigen
monoclonal antibody J591 (177Lu-J591) for metastatic
castration-resistant prostate cancer. Urol Oncol.
38:848.e9–848.e16. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Shin D, Ha S, O JH, Rhew SA, Yoon CE, Kwon
HJ, Moon HW, Park YH, Park SY, Park C, et al: A single dose of
novel PSMA-targeting radiopharmaceutical agent
[177Lu]ludotadipep for patients with metastatic
castration-resistant prostate cancer: Phase i clinical trial.
Cancers (Basel). 14(6225)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jacoba IM and Weber HC: Biomarkers in
gastroenteropancreatic neuroendocrine neoplasms. Curr Opin
Endocrinol Diabetes Obes. 30:175–180. 2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Fernandes CJ, Leung G, Eads JR and Katona
BW: Gastroenteropancreatic neuroendocrine tumors. Gastroenterol
Clin North Am. 51:625–647. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Liu M, Wei L, Liu W, Chen S, Guan M, Zhang
Y, Guo Z, Liu R and Xie P: Trends in incidence and survival in
patients with gastrointestinal neuroendocrine tumors: A SEER
database analysis, 1977-2016. Front Oncol.
13(1079575)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Harris PE and Zhernosekov K: The evolution
of PRRT for the treatment of neuroendocrine tumors; What comes
next? Front Endocrinol (Lausanne). 13(941832)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Theodoropoulou M and Stalla GK:
Somatostatin receptors: From signaling to clinical practice. Front
Neuroendocrinol. 34:228–252. 2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ichikawa Y, Kobayashi N, Takano S, Kato I,
Endo K and Inoue T: Neuroendocrine tumor theranostics. Cancer Sci.
113:1930–1938. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Pokuri VK, Fong MK and Iyer R: Octreotide
and lanreotide in gastroenteropancreatic neuroendocrine tumors.
Curr Oncol Rep. 18(7)2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Das S, Al-Toubah T, El-Haddad G and
Strosberg J: 177Lu-DOTATATE for the treatment of
gastroenteropancreatic neuroendocrine tumors. Expert Rev
Gastroenterol Hepatol. 13:1023–1031. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Strosberg J, El-Haddad G, Wolin E,
Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H,
et al: Phase 3 trial of 177Lu-Dotatate for midgut
neuroendocrine tumors. N Engl J Med. 376:125–135. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Strosberg JR, Caplin ME, Kunz PL,
Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC,
Pavel ME, et al: 177Lu-Dotatate plus long-acting
octreotide versus high-dose long-acting octreotide in patients with
midgut neuroendocrine tumours (NETTER-1): Final overall survival
and long-term safety results from an open-label, randomised,
controlled, phase 3 trial. Lancet Oncol. 22:1752–1763.
2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Khan MS, Stamp E, Sammon C, Brabander T,
de Herder WW and Pavel ME: Matching-adjusted indirect treatment
comparison of [177Lu]Lu-DOTA-TATE, everolimus and
sunitinib in advanced, unresectable gastroenteropancreatic
neuroendocrine tumours: Relative effectiveness of
[177Lu]Lu-DOTA-TATE in gastroenteropancreatic
neuroendocrine tumours. EJC Suppl. 16:5–13. 2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Alsadik S, Gnanasegaran G, Chen L, Quigley
AM, Mandair D, Toumpanakis C, Caplin M and Navalkissoor S: Safety
and efficacy of 177 Lu-DOTATATE in neuroendocrine tumor patients
with extensive bone disease. Clin Nucl Med. 48:667–672.
2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Albrecht J, Exner S, Grötzinger C, Prasad
S, Konietschke F, Beindorff N, Kühl AA, Prasad V, Brenner W and
Koziolek EJ: Multimodal imaging of 2-cycle PRRT with
177Lu-DOTA-JR11 and 177Lu-DOTATOC in an
orthotopic neuroendocrine xenograft tumor mouse model. J Nucl Med.
62:393–398. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mansi R, Plas P, Vauquelin G and Fani M:
Distinct in vitro binding profile of the somatostatin receptor
subtype 2 antagonist [177Lu]Lu-OPS201 compared to the
agonist [177Lu]Lu-DOTA-TATE. Pharmaceuticals (Basel).
14(1265)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zboralski D, Hoehne A, Bredenbeck A,
Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C,
von Hacht JL, et al: Preclinical evaluation of FAP-2286 for
fibroblast activation protein targeted radionuclide imaging and
therapy. Eur J Nucl Med Mol Imaging. 49:3651–3667. 2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zboralski D, Osterkamp F, Christensen E,
Bredenbeck A, Schumann A, Hoehne A, Schneider E, Paschke M,
Ungewiss J, Haase C, et al: Fibroblast activation protein targeted
radiotherapy induces an immunogenic tumor microenvironment and
enhances the efficacy of PD-1 immune checkpoint inhibition. Eur J
Nucl Med Mol Imaging. 50:2621–2635. 2023.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Baum RP, Schuchardt C, Singh A,
Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel
F, Zboralski D, et al: Feasibility, biodistribution, and
preliminary dosimetry in peptide-targeted radionuclide therapy of
diverse adenocarcinomas using 177Lu-FAP-2286:
First-in-humans results. J Nucl Med. 63:415–423. 2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Minczeles NS, Bos EM, de Leeuw RC, Kros
JM, Konijnenberg MW, Bromberg JEC, de Herder WW, Dirven CMF,
Hofland J and Brabander T: Efficacy and safety of peptide receptor
radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15
patients with progressive treatment-refractory meningioma. Eur J
Nucl Med Mol Imaging. 50:1195–1204. 2023.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Nishida H, Kondo Y, Kusaba T, Kadowaki H
and Daa T: Immunohistochemical reactivity of prostate-specific
membrane antigen in salivary gland tumors. Head Neck Pathol.
16:427–433. 2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
van Boxtel W, Uijen MJM, Verhaegh GW,
Willems SM and Jonker MA: PALGA Group. Schalken JA, van Engen-van
Grunsven ICH and van Herpen CML: Prognostic value of PSMA, c-MET
and E-cadherin in salivary duct carcinoma. Oral Oncol.
110(105018)2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
van Boxtel W, Lütje S, van Engen-van
Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, Nagarajah J,
Gotthardt M and van Herpen CML: 68Ga-PSMA-HBED-CC PET/CT
imaging for adenoid cystic carcinoma and salivary duct carcinoma: A
phase 2 imaging study. Theranostics. 10:2273–2283. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Uijen MJM, Derks YHW, Merkx RIJ, Schilham
MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M,
Heskamp S, et al: PSMA radioligand therapy for solid tumors other
than prostate cancer: Background, opportunities, challenges, and
first clinical reports. Eur J Nucl Med Mol Imaging. 48:4350–4368.
2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Lütje S, Sauerwein W, Lauenstein T,
Bockisch A and Poeppel TD: In vivo visualization of
prostate-specific membrane antigen in adenoid cystic carcinoma of
the salivary gland. Clin Nucl Med. 41:476–477. 2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Klein Nulent TJW, van Es RJJ, Willems SM,
Braat AJAT, Devriese LA, de Bree R and de Keizer B: First
experiences with 177Lu-PSMA-617 therapy for recurrent or
metastatic salivary gland cancer. EJNMMI Res.
11(126)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Terroir M, Lamesa C, Krim M, Vija L,
Texier JS, Cassou-Mounat T, Delord JP, Vallot D and Courbon F:
Radioligand therapy with [177Lu]Lu-PSMA-617 for salivary
gland cancers: Literature review and first compassionate use in
France. Pharmaceuticals (Basel). 16(754)2023.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Lütje S, Gomez B, Cohnen J, Umutlu L,
Gotthardt M, Poeppel TD, Bockisch A and Rosenbaum-Krumme S: Imaging
of prostate-specific membrane antigen expression in metastatic
differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT. Clin
Nucl Med. 42:20–25. 2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Lawhn-Heath C, Yom SS, Liu C,
Villanueva-Meyer JE, Aslam M, Smith R, Narwal M, Juarez R, Behr SC,
Pampaloni MH, et al: Gallium-68 prostate-specific membrane antigen
([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: A
feasibility study. EJNMMI Res. 10(128)2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sollini M, Kirienko M, di Tommaso L, Pini
C, Gelardi F, Ariano S, Lania AG, Mazziotti G, Mercante G and Chiti
A: The complementary role of PSMA expression and
[18F]FDG PET/CT in predicting thyroid cancer outcome:
From black and white to shades of gray, in the era of precision
oncology. EJNMMI Res. 13(54)2023.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Pitalua-Cortes Q, García-Perez FO,
Vargas-Ahumada J, Gonzalez-Rueda S, Gomez-Argumosa E,
Ignacio-Alvarez E, Soldevilla-Gallardo I and Torres-Agredo L:
Head-to-head comparison of 68Ga-PSMA-11 and 131I in the
follow-up of well-differentiated metastatic thyroid cancer: A new
potential theragnostic agent. Front Endocrinol (Lausanne).
12(794759)2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Assadi M and Ahmadzadehfar H:
177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy
in a patient with advanced metastatic radioiodine-refractory
differentiated thyroid cancer after failure of tyrosine kinase
inhibitors treatment. World J Nucl Med. 18:406–408. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
de Vries LH, Lodewijk L, Braat AJAT,
Krijger GC, Valk GD, Lam MGEH, Borel Rinkes IHM, Vriens MR and de
Keizer B: 68Ga-PSMA PET/CT in radioactive
iodine-refractory differentiated thyroid cancer and first treatment
results with 177Lu-PSMA-617. EJNMMI Res.
10(18)2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Pastoreková S, Parkkila S, Parkkila AK,
Opavský R, Zelník V, Saarnio J and Pastorek J: Carbonic anhydrase
IX, MN/CA IX: Analysis of stomach complementary DNA sequence and
expression in human and rat alimentary tracts. Gastroenterology.
112:398–408. 1997.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Steffens MG, Oosterwijk-Wakka JC,
Zegwaart-Hagemeier NE, Boerman OC, Debruyne FM, Corstens FH and
Oosterwijk E: Immunohistochemical analysis of tumor antigen
saturation following injection of monoclonal antibody G250.
Anticancer Res. 19:1197–1200. 1999.PubMed/NCBI
|
|
68
|
Stillebroer AB, Boerman OC, Desar IME,
Boers-Sonderen MJ, van Herpen CML, Langenhuijsen JF, Smith-Jones
PM, Oosterwijk E, Oyen WJ and Mulders PF: Phase 1
radioimmunotherapy study with lutetium 177-labeled anti-carbonic
anhydrase IX monoclonal antibody girentuximab in patients with
advanced renal cell carcinoma. Eur Urol. 64:478–485.
2013.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Muselaers CH, Boers-Sonderen MJ, van
Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF,
van Herpen CM, Langenhuijsen JF, Oosterwijk E, et al: Phase 2 study
of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal
antibody girentuximab in patients with advanced renal cell
carcinoma. Eur Urol. 69:767–770. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Elboga U, Kilbas B, Sahin E, Cayırlı YB,
Eryilmaz K, Begec T, Bakar HE, Mercanoglu G and Celen YZ: An
automated synthesis of 177Lu-EDTMP as an efficient bone-seeking
therapeutic radiopharmaceutical. Eur Rev Med Pharmacol Sci.
25:4829–4834. 2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Askari E, Harsini S, Vahidfar N, Divband G
and Sadeghi R: 177Lu-EDTMP for metastatic bone pain
palliation: A systematic review and meta-analysis. Cancer Biother
Radiopharm. 36:383–390. 2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Mercanoglu G, Zilbeyaz K and Arslan N:
Synthesis and ready to use kit formulation of EDTMP for the
preparation of 177Lu-EDTMP as a bone palliation
radiopharmaceutical. Curr Radiopharm. 16:38–43. 2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Chen H, Zhao L, Fu K, Lin Q, Wen X,
Jacobson O, Sun L, Wu H, Zhang X, Guo Z, et al: Integrin
αvβ3-targeted radionuclide therapy combined
with immune checkpoint blockade immunotherapy synergistically
enhances anti-tumor efficacy. Theranostics. 9:7948–7960.
2019.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Kim C, Liu SV, Subramaniam DS, Torres T,
Loda M, Esposito G and Giaccone G: Phase I study of the
177Lu-DOTA0-Tyr3-octreotate
(lutathera) in combination with nivolumab in patients with
neuroendocrine tumors of the lung. J Immunother Cancer.
8(e000980)2020.PubMed/NCBI View Article : Google Scholar
|
